vs
Immunocore Holdings plc（IMCR）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
Immunocore Holdings plc的季度营收约是RE/MAX Holdings, Inc.的1.5倍（$104.5M vs $71.1M），Immunocore Holdings plc同比增速更快（24.3% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $-35.5M），过去两年Immunocore Holdings plc的营收复合增速更高（21.7% vs -4.7%）
Immunocore是一家处于商业化阶段的全球生物技术企业，总部位于英国牛津郡，依托可溶性T细胞受体技术深耕生物药物的研发领域，其创新技术平台为肿瘤、感染性疾病、自身免疫性疾病等多领域的新药开发提供支撑。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
IMCR vs RMAX — 直观对比
营收规模更大
IMCR
是对方的1.5倍
$71.1M
营收增速更快
IMCR
高出26.1%
-1.8%
自由现金流更多
RMAX
多$69.0M
$-35.5M
两年增速更快
IMCR
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $104.5M | $71.1M |
| 净利润 | — | $1.4M |
| 毛利率 | 97.4% | — |
| 营业利润率 | -18.8% | 13.1% |
| 净利率 | — | 2.0% |
| 营收同比 | 24.3% | -1.8% |
| 净利润同比 | — | -75.2% |
| 每股收益（稀释后） | $-0.61 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMCRRMAX
| Q4 25 | $104.5M | $71.1M | ||
| Q3 25 | $103.7M | $73.2M | ||
| Q2 25 | $98.0M | $72.8M | ||
| Q1 25 | $93.9M | $74.5M | ||
| Q4 24 | $84.1M | $72.5M | ||
| Q3 24 | $80.2M | $78.5M | ||
| Q2 24 | $75.4M | $78.5M | ||
| Q1 24 | $70.5M | $78.3M |
净利润IMCRRMAX
| Q4 25 | — | $1.4M | ||
| Q3 25 | $-177.0K | $4.0M | ||
| Q2 25 | $-10.3M | $4.7M | ||
| Q1 25 | $5.0M | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $8.7M | $966.0K | ||
| Q2 24 | $-11.6M | $3.7M | ||
| Q1 24 | $-24.4M | $-3.4M |
毛利率IMCRRMAX
| Q4 25 | 97.4% | — | ||
| Q3 25 | 99.5% | — | ||
| Q2 25 | 98.9% | — | ||
| Q1 25 | 99.1% | — | ||
| Q4 24 | 99.6% | — | ||
| Q3 24 | 99.4% | — | ||
| Q2 24 | 97.7% | — | ||
| Q1 24 | 99.7% | — |
营业利润率IMCRRMAX
| Q4 25 | -18.8% | 13.1% | ||
| Q3 25 | -6.9% | 25.0% | ||
| Q2 25 | -15.2% | 19.3% | ||
| Q1 25 | -3.9% | 7.2% | ||
| Q4 24 | -23.1% | 5.9% | ||
| Q3 24 | -10.6% | 19.4% | ||
| Q2 24 | -21.2% | 20.6% | ||
| Q1 24 | -37.6% | 5.8% |
净利率IMCRRMAX
| Q4 25 | — | 2.0% | ||
| Q3 25 | -0.2% | 5.4% | ||
| Q2 25 | -10.5% | 6.4% | ||
| Q1 25 | 5.4% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | 10.9% | 1.2% | ||
| Q2 24 | -15.4% | 4.7% | ||
| Q1 24 | -34.7% | -4.3% |
每股收益（稀释后）IMCRRMAX
| Q4 25 | $-0.61 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $-0.20 | — | ||
| Q1 25 | $0.10 | — | ||
| Q4 24 | $-0.47 | — | ||
| Q3 24 | $0.17 | — | ||
| Q2 24 | $-0.23 | — | ||
| Q1 24 | $-0.49 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $864.2M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $381.0M | $452.4M |
| 总资产 | $1.1B | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资IMCRRMAX
| Q4 25 | $864.2M | $118.7M | ||
| Q3 25 | $892.4M | $107.5M | ||
| Q2 25 | $882.8M | $94.3M | ||
| Q1 25 | $837.0M | $89.1M | ||
| Q4 24 | $820.4M | $96.6M | ||
| Q3 24 | $901.3M | $83.8M | ||
| Q2 24 | $859.6M | $66.1M | ||
| Q1 24 | $832.8M | $82.1M |
总债务IMCRRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | $438.7M | $437.2M | ||
| Q2 24 | $452.5M | $438.1M | ||
| Q1 24 | $452.5M | $439.0M |
股东权益IMCRRMAX
| Q4 25 | $381.0M | $452.4M | ||
| Q3 25 | $396.6M | $448.1M | ||
| Q2 25 | $388.5M | $442.4M | ||
| Q1 25 | $378.5M | $433.5M | ||
| Q4 24 | $360.7M | $429.5M | ||
| Q3 24 | $377.8M | $423.1M | ||
| Q2 24 | $359.1M | $418.4M | ||
| Q1 24 | $359.5M | $412.0M |
总资产IMCRRMAX
| Q4 25 | $1.1B | $582.5M | ||
| Q3 25 | $1.1B | $582.2M | ||
| Q2 25 | $1.1B | $574.8M | ||
| Q1 25 | $1.0B | $571.4M | ||
| Q4 24 | $1.0B | $581.6M | ||
| Q3 24 | $1.1B | $578.6M | ||
| Q2 24 | $1.0B | $571.4M | ||
| Q1 24 | $994.0M | $566.7M |
负债/权益比IMCRRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | 1.16× | 1.03× | ||
| Q2 24 | 1.26× | 1.05× | ||
| Q1 24 | 1.26× | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-32.7M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $-35.5M | $33.5M |
| 自由现金流率自由现金流/营收 | -34.0% | 47.1% |
| 资本支出强度资本支出/营收 | 2.8% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-15.1M | $56.8M |
8季度趋势，按日历期对齐
经营现金流IMCRRMAX
| Q4 25 | $-32.7M | $40.9M | ||
| Q3 25 | $-4.5M | $17.7M | ||
| Q2 25 | $26.0M | $4.6M | ||
| Q1 25 | $435.0K | $5.7M | ||
| Q4 24 | $-14.0M | $59.7M | ||
| Q3 24 | $21.1M | $17.6M | ||
| Q2 24 | $23.5M | $15.9M | ||
| Q1 24 | $-4.6M | $9.4M |
自由现金流IMCRRMAX
| Q4 25 | $-35.5M | $33.5M | ||
| Q3 25 | $-5.2M | $16.4M | ||
| Q2 25 | $25.6M | $2.9M | ||
| Q1 25 | $137.0K | $4.0M | ||
| Q4 24 | $-17.5M | $53.0M | ||
| Q3 24 | $20.3M | $16.3M | ||
| Q2 24 | $23.1M | $14.0M | ||
| Q1 24 | $-5.0M | $6.8M |
自由现金流率IMCRRMAX
| Q4 25 | -34.0% | 47.1% | ||
| Q3 25 | -5.0% | 22.4% | ||
| Q2 25 | 26.1% | 4.0% | ||
| Q1 25 | 0.1% | 5.3% | ||
| Q4 24 | -20.9% | 73.2% | ||
| Q3 24 | 25.3% | 20.8% | ||
| Q2 24 | 30.7% | 17.8% | ||
| Q1 24 | -7.1% | 8.6% |
资本支出强度IMCRRMAX
| Q4 25 | 2.8% | 10.4% | ||
| Q3 25 | 0.7% | 1.8% | ||
| Q2 25 | 0.4% | 2.2% | ||
| Q1 25 | 0.3% | 2.3% | ||
| Q4 24 | 4.3% | 9.1% | ||
| Q3 24 | 1.0% | 1.7% | ||
| Q2 24 | 0.4% | 2.4% | ||
| Q1 24 | 0.6% | 3.3% |
现金转化率IMCRRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | 0.09× | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | 2.42× | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMCR
暂无分部数据
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
